iHateHospitals.com

MEDICAL NEWS: If a trial is adequately powered for two clinically important endpoints, A and B, each of which can fully characterize a treatment benefit to support a regulatory claim by itself, then both endpoints are usually labeled primary, and the trial is deemed positive if either endpoint is statistically significant after a multiplicity [...]

CANCER NEWS: NORWALK, Conn. — The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection. Paul Richardson, MD, Clinical Director of the Jerome [...]

MEDICAL NEWS: This article presents a new approach to the problem of deriving an optimal design for a randomized group sequential clinical trial based on right-censored event times. We are motivated by the fact that, if the proportional hazards assumption is not met, then a conventional design’s actual power can differ substantially from its [...]

(Mesothelioma News) ROCKVILLE, Md. — Human Genome Sciences, Inc. today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy (serious, serious drugs) agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). “There is [...]

(Mesothelioma News) The biotech company that Justin Murdock, the son of Dole Food Co. owner David Murdock, leads has begun stage-III clinical trials for a lung cancer vaccine. NovaRx, based in San Diego, is testing its Lucanix vaccine in about 700 patients with lung cancer — a disease which the American Cancer Society says is [...]

DRUGS & RX: ANTONY, France, August 27, 2008 /PRNewswire-FirstCall/ –
- Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber
Stallergenes S.A. announces the highly positive results of a…

View the source of this article…

Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber was another [...]

DRUGS & RX: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug 27, 2008 - Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced the publication of preclinical data…

View the source of this article…

Curis Announces Nature Publication Elucidating a Paracrine Mechanism of Action in Hedgehog-Expressing Tumors was another wonderful [...]

DRUGS & RX: Studies demonstrate efficacy and safety of VisonacTM and the potential for a simplified Photodynamic Therapy (PDT) procedure for treatment of moderate to severe acne
Oslo, Norway, August 27, 2008 - Photocure announces positive preliminary results…

View the source of this article…

Photocure Announces Positive Phase II Results with Visonac for Acne was another wonderful and [...]

DRUGS & RX: INDIANAPOLIS, August 26, 2008 /PRNewswire/ — Semafore Pharmaceuticals Inc. presented data at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., announcing the discovery of novel multi-targeted kinase inhibitors…

View the source of this article…

Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors was another wonderful and informative drug and pharmaceutical article [...]

DRUGS & RX: LONDON, 27 August 2008: Ark Therapeutics Group plc (“Ark” or the “Company”) today nnounces that enrolment of patients into its Phase III pilot study for VitorTM (Study 208) has commenced. VitorTM is Ark’s product to…

View the source of this article…

Ark’s Vitor commences patient enrolment into Phase III pilot study was another wonderful [...]

DRUGS & RX: PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–Aug 26, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The companies announced that new Phase II data…

View the source of this article…

Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program [...]

DRUGS & RX: Study led by Hollings Cancer Center researcher finds risk greatest in ages 25-44
CHARLESTON, S.C., Aug. 26 /PRNewswire/ — Individuals with a history of nonmelanoma skin cancer (NMSC), especially those who had it at a younger age, are at…

View the source of this article…

Individuals With History of Nonmelanoma Skin Cancer at Greater Risk [...]